Gilead and Cartography enter deal to develop cancer therapies
License out/in
Preview
Source: Pharmaceutical Technology
Gilead and Cartography will develop treatments for triple-negative breast cancer and adenocarcinoma. Credit: JHVEPhoto / Shutterstock.com.
Cartography Biosciences has announced a strategic partnership with Gilead Sciences, focusing on the discovery and development of therapies against new targets and target pairs in the oncology field.
Recommended Buyer's Guides
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Packaging Materials, Containers and Containment Services for the Pharmaceutical Industry
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Compliance Software for the Pharmaceutical Industry
The alliance aims to create treatments for triple-negative breast cancer and adenocarcinoma, the most prevalent form of non-small cell lung cancer.
Cartography’s computational and genomics platforms, ATLAS and SUMMIT, will be leveraged to discover and establish new tumour-selective target antigens and pairs of antigens.
These platforms combine single-cell data from healthy reference and tumour atlases [maps that describe the multidimensional cellular, structural and molecular characteristics of unaffected tissue and of cancerous tissue], applying algorithms to identify targets specific to the intended target cells and streamlined for therapeutic programmes.
During the multi-year partnership, Gilead can opt-in on multiple targets detected through this deal.
See Also:Agios sells vorasidenib US royalties for $905m
Preview
Source: Pharmaceutical Technology
BIOSECURE “grandfather” amendment softens impact of US-China trade ban
Preview
Source: Pharmaceutical Technology
Gilead will be responsible for the subsequent research, development and commercialisation of the programmes against these targets.
Cartography will receive $20m in an upfront payment and additional near-term preclinical milestone payments. It will then also receive payments on meeting development, regulatory and commercial milestones, and royalty payments on net product sales for Gilead programmes against each optioned target.
Cartography Biosciences CEO Kevin Parker stated: “We are excited to partner with Gilead to identify novel and compelling antigen targets using our ATLAS and SUMMIT platform.
“The current target landscape in oncology is growing increasingly crowded and there is an urgent need to provide patients with innovative, targeted medicines. Cartography looks forward to working with Gilead and leveraging the team’s expertise in oncology and drug development to identify tumour-specific targets and target pairs that can lead to transformative therapies for patients.”
In March 2024, Gilead and Xilio Therapeutics declared an exclusive licence agreement for the development of a tumour-activated IL-12 programme.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.